Early Neurological Outcome in Newborns With Mild Encephalopathy:a Regional Network
1 other identifier
observational
27
1 country
1
Brief Summary
This is a multicenter prospective observational study that aims to determine the natural history of patients with early diagnosis (within 6 hours of life) of mild hipoxic ischemic encephalopaty (HIE), who are not candidates for treatment with therapeutic hypothermia. The goal of this study is to learn about the early neurological outcome in babies with mild encephalopathy, as recent studies have shown how there is an increased risk of brain damage with a high incidence of resonance magnetic nuclear (RMN) anomalies and possible neurodevelopmental complications including learning or neuropsychological disorders, epilepsy, visual and sensory deficits. The main question aimed to answer is the identification of early possible predictive factors for an unfavorable outcome in order to undertake early rehabilitation programs and for the future planning of trials on early neuroprotection in the investigated population. Babies with early diagnosis (within 6h of life) of mild grade HIE not candidate for hypothermic treatment are subjected to clinical and instrumental assessments during the neonatal period:
- neurological objective exam according to the modified "Sarnat" score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation;
- an Amplitude Electroencephalogram (aEEG) study within 6 hours of life, for 6 hours;
- cerebral ultrasound within 6 hours of life, in the third and seventh day of life;
- a brain magnetic resonance imaging study between the seventh and 14th day of life;
- an Electroencephalogram (EEG) evaluation within 7 days. After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age:
- Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements;
- evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month;
- EEG evaluation at the 6th and 12th month.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 7, 2022
CompletedFirst Submitted
Initial submission to the registry
March 2, 2023
CompletedFirst Posted
Study publicly available on registry
March 27, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedMarch 27, 2023
March 1, 2023
2.7 years
March 2, 2023
March 14, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
early neurological outcome
the percentage of patients with mild asphyxia with evidence of brain damage, defined by MRI
between the seventh and 14th day of life
early neurological outcome
the percentage of patients with mild asphyxia with evidence of brain damage, defined by EEG abnormalities
at the 6th month
early neurological outcome
the percentage of patients with mild asphyxia with evidence of brain damage, defined by EEG abnormalities
at 12th month.
early neurological outcome
the percentage of patients with mild asphyxia with evidence of brain damage, defined by neurological examination
at the 3th month
early neurological outcome
the percentage of patients with mild asphyxia with evidence of brain damage, defined by neurological examination
at the 6th month.
early neurological outcome
the percentage of patients with mild asphyxia with evidence of brain damage, defined by neurological examination
at the 12th month.
Secondary Outcomes (4)
Electroencephalographic and epilepsy outcome
between the 6 hours of life and 12th month.
Neurodevelopmental outcome
12th month
Hospitalization
between birth until 12th month
adverse events
between birth until 12th month
Study Arms (1)
Patients with early diagnosis (within 6 hours of life) of mild HIE
Interventions
During the neonatal period: neurological objective exam according to the modified Sarnat score, Thompson score and Hammersmith Neonatal Neurological Examination (HINE) within 6 hours of life, 24 hours of life and before resignation; an AEEG study within 6 hours of life, for 6 hours; cerebral ultrasound within 6 hours of life, in the third and seventh day of life; a brain magnetic resonance imaging study between the seventh and 14th day of life; an EEG evaluation within 7 days. After resignation, all patients will be included in a minimum duration follow-up program of 12 months, with assessments at 3rd, 6th and 12th month of age: Hammersmith Neonatal Neurological Examination (HINE) and evaluation of the General Movements; evaluation of psychomotor development through Griffiths/Bayley III scales at the 12th month; EEG evaluation at the 6th and 12th month.
Eligibility Criteria
patients with early diagnosis (within 6 hours of life) of mild HIE, who are not candidates for treatment with therapeutic hypothermia
You may qualify if:
- patients born after the 36th week of gestational age, with signs of encephalopathy found between the 10th minute of life and 6h, presenting with one or more of the following signs of intrapartum hypoxia with a potential of hydrogeb (pH) ≤ 7 or an excess of bases (BE) ≥ 12 mmol/l in the first hour of life, measured on cord or arterial blood or an abnormal course of delivery (eg: fetal heart rate abnormalities, cord prolapse, uterine tear, haemorrhage/ trauma/ convulsive seizures/ maternal cardiorespiratory arrest; shoulder dystocia; meconium-dyed amniotic fluid or protracted second stage and the presence of an Apgar at 10 min ≤5 or the need for continuous respiratory support at 10 minutes.
You may not qualify if:
- mutes neurological objectivity;
- impossibility of recruitment within 6h;
- major congenital anomalies, brain malformations;
- neonatal abstinence syndrome;
- metabolic encephalopathies and severe growth restriction (birth weight ≤1800g);
- treatment with therapeutic hypothermia;
- refusal of consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fondazione Policlinico Universitario Agostino Gemelli -IRRCS
Rome, 00168, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Domenico M Romeo, MD,PHD
ChatolicUIT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor, Principal investigator
Study Record Dates
First Submitted
March 2, 2023
First Posted
March 27, 2023
Study Start
February 27, 2020
Primary Completion
November 7, 2022
Study Completion
December 31, 2024
Last Updated
March 27, 2023
Record last verified: 2023-03